Trial: 202009128

A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects with Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas

Phase

I (Cancer Control)

Principal Investigator

Johanns, Tanner

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov